PMC:7546122 / 9113-9600 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T42","span":{"begin":160,"end":166},"obj":"Body_part"},{"id":"T43","span":{"begin":271,"end":277},"obj":"Body_part"},{"id":"T44","span":{"begin":432,"end":438},"obj":"Body_part"}],"attributes":[{"id":"A42","pred":"fma_id","subj":"T42","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A43","pred":"fma_id","subj":"T43","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A44","pred":"fma_id","subj":"T44","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"In contrast, HCoV-229E nAb titers between 1:43 and 1:196 (mean = 1:98) were measured for the 54 IVIG lots tested (Figure 1B). IVIG lots produced from recovered plasma contained significantly higher levels of nAb to HCoV-229E as compared to IVIG lots produced from source plasma, independent of the geographic origin. A significant, although quantitatively minor, difference was also found between IVIG lots manufactured from source plasma collected in either the United States or Europe."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T85","span":{"begin":106,"end":112},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T86","span":{"begin":160,"end":166},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T87","span":{"begin":271,"end":277},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T88","span":{"begin":317,"end":318},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T89","span":{"begin":432,"end":438},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"In contrast, HCoV-229E nAb titers between 1:43 and 1:196 (mean = 1:98) were measured for the 54 IVIG lots tested (Figure 1B). IVIG lots produced from recovered plasma contained significantly higher levels of nAb to HCoV-229E as compared to IVIG lots produced from source plasma, independent of the geographic origin. A significant, although quantitatively minor, difference was also found between IVIG lots manufactured from source plasma collected in either the United States or Europe."}

{"project":"LitCovid-sentences","denotations":[{"id":"T62","span":{"begin":0,"end":125},"obj":"Sentence"},{"id":"T63","span":{"begin":126,"end":316},"obj":"Sentence"},{"id":"T64","span":{"begin":317,"end":487},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In contrast, HCoV-229E nAb titers between 1:43 and 1:196 (mean = 1:98) were measured for the 54 IVIG lots tested (Figure 1B). IVIG lots produced from recovered plasma contained significantly higher levels of nAb to HCoV-229E as compared to IVIG lots produced from source plasma, independent of the geographic origin. A significant, although quantitatively minor, difference was also found between IVIG lots manufactured from source plasma collected in either the United States or Europe."}

{"project":"LitCovid-PubTator","denotations":[{"id":"160","span":{"begin":13,"end":22},"obj":"Species"},{"id":"161","span":{"begin":215,"end":224},"obj":"Species"}],"attributes":[{"id":"A160","pred":"tao:has_database_id","subj":"160","obj":"Tax:11137"},{"id":"A161","pred":"tao:has_database_id","subj":"161","obj":"Tax:11137"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In contrast, HCoV-229E nAb titers between 1:43 and 1:196 (mean = 1:98) were measured for the 54 IVIG lots tested (Figure 1B). IVIG lots produced from recovered plasma contained significantly higher levels of nAb to HCoV-229E as compared to IVIG lots produced from source plasma, independent of the geographic origin. A significant, although quantitatively minor, difference was also found between IVIG lots manufactured from source plasma collected in either the United States or Europe."}